Immunovant Reports Financial Results for the Quarter Ended December 31, 2024
Provided By GlobeNewswire
Last update: Feb 6, 2025
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal third quarter ended December 31, 2024.
Read more at globenewswire.com
